Interleukin 1 beta inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Interleukin 1 Beta Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 11+ companies and 12+ pipeline drugs in Interleukin 1 Beta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Interleukin 1 Beta Inhibitors: Overview
Interleukin 1 Beta Inhibitors is a potent pro-inflammatory cytokine produced by cells of the innate immune system. Interleukin 1 beta (IL-1?) is produced as an inactive 31 kDa precursor, termed pro-IL-1?, in response to molecular motifs carried by pathogens called ‘pathogen associated molecular patterns’ (PAMPs). It is a major cytokine involved in monocyte activation and activation of proinflammatory signaling pathways in peripheral tissues and brain. IL-1? expression and its secretion are tightly regulated. IL-1? is a master regulator of inflammation via controlling a variety of innate immune processes. IL-1 has a wide range of biological functions, which include acting as a leukocytic pyrogen, a mediator of fever and a leukocytic endogenous mediator, and an inducer of several components of the acute-phase response and lymphocyte-activating factor (LAF). The blocking of IL-1 could be effective strategies for the management of classic autoimmune diseases and autoinflammatory diseases.
Report Highlights
This segment of the Interleukin 1 Beta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin 1 Beta Inhibitors Emerging Drugs
Further product details are provided in the report……..
Interleukin 1 Beta Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin 1 Beta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Interleukin 1 Beta Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 1 Beta Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 1 Beta Inhibitors drugs.
Interleukin 1 Beta Inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Interleukin 1 Beta Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 11+ companies and 12+ pipeline drugs in Interleukin 1 Beta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Interleukin 1 Beta Inhibitors: Overview
Interleukin 1 Beta Inhibitors is a potent pro-inflammatory cytokine produced by cells of the innate immune system. Interleukin 1 beta (IL-1?) is produced as an inactive 31 kDa precursor, termed pro-IL-1?, in response to molecular motifs carried by pathogens called ‘pathogen associated molecular patterns’ (PAMPs). It is a major cytokine involved in monocyte activation and activation of proinflammatory signaling pathways in peripheral tissues and brain. IL-1? expression and its secretion are tightly regulated. IL-1? is a master regulator of inflammation via controlling a variety of innate immune processes. IL-1 has a wide range of biological functions, which include acting as a leukocytic pyrogen, a mediator of fever and a leukocytic endogenous mediator, and an inducer of several components of the acute-phase response and lymphocyte-activating factor (LAF). The blocking of IL-1 could be effective strategies for the management of classic autoimmune diseases and autoinflammatory diseases.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin 1 Beta Inhibitors R&D. The therapies under development are focused on novel approaches for Interleukin 1 Beta Inhibitors.
This segment of the Interleukin 1 Beta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin 1 Beta Inhibitors Emerging Drugs
- Gevokizumab: Novartis
- Goflikicept: TRPHARM
Further product details are provided in the report……..
Interleukin 1 Beta Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin 1 Beta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Interleukin 1 Beta Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Interleukin 1 Beta Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Interleukin 1 Beta Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin 1 Beta Inhibitors drugs.
Interleukin 1 Beta Inhibitors Report Insights
- Interleukin 1 Beta Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Interleukin 1 Beta Inhibitors drugs?
- How many Interleukin 1 Beta Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Interleukin 1 Beta Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin 1 Beta Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Interleukin 1 Beta Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis
- Regeneron Pharmaceuticals
- TRPHARM
- Hutchison MediPharma
- Tetra Bio Pharma
- Jiangsu T-mab BioPharma
- Flame Biosciences
- Canakinumab
- Rilonacept
- Gevokizumab
- Goflikicept
- HMPL-004
- HU 308
- TK 002
- FL-101 Flame Biosciences
Introduction
Executive Summary
Interleukin 1 Beta Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Interleukin 1 Beta Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Interleukin 1 Beta Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Interleukin 1 Beta Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Goflikicept: TRPHARM
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Gevokizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
FL-101: Flame Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin 1 Beta Inhibitors Key Companies
Interleukin 1 Beta Inhibitors Key Products
Interleukin 1 Beta Inhibitors- Unmet Needs
Interleukin 1 Beta Inhibitors- Market Drivers and Barriers
Interleukin 1 Beta Inhibitors- Future Perspectives and Conclusion
Interleukin 1 Beta Inhibitors Analyst Views
Interleukin 1 Beta Inhibitors Key Companies
Appendix
Executive Summary
Interleukin 1 Beta Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Interleukin 1 Beta Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Interleukin 1 Beta Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Interleukin 1 Beta Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Goflikicept: TRPHARM
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Gevokizumab: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
FL-101: Flame Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin 1 Beta Inhibitors Key Companies
Interleukin 1 Beta Inhibitors Key Products
Interleukin 1 Beta Inhibitors- Unmet Needs
Interleukin 1 Beta Inhibitors- Market Drivers and Barriers
Interleukin 1 Beta Inhibitors- Future Perspectives and Conclusion
Interleukin 1 Beta Inhibitors Analyst Views
Interleukin 1 Beta Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Interleukin 1 Beta Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Interleukin 1 Beta Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Interleukin 1 Beta Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Interleukin 1 Beta Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products